Ga-PDT02 as a promising uPAR-targeted PET radiotracer with favorable pharmacokinetics and imaging performance, supporting its potential utility for non-invasive visualization of uPAR expression in aggressive tumors.
Zhou et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: